Radiopharmaceutical Agent Shows Efficacy, Tolerability in SSTR2+ NETs
Brandon R. Mancini, MD, MBA, FACRO, discussed results from a phase 1/2a trial that evaluated [212Pb]VMT-α-NET in patients with advanced NETs.
Related Articles
ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm
From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.
Adding Retifanlimab to Chemo Yields Clinical Benefit in Inoperable SCAC
Results from the phase 3 POD1UM-303/InterAACT-2 trial demonstrated improved PFS and OS in patients with locally recurrent or metastatic SCAC.
Nadunolimab Earns FDA Fast-Track Designation in Metastatic PDAC
The FDA decision follows phase 2 CANFOUR trial data showing a 2-year survival rate of 35% in IL1RAP-high metastatic pancreatic ductal adenocarcinoma.
Frontline Nivolumab Combo Shows Enduring Activity in MSI-H Gastric Cancer
Phase 2 data may support nivolumab plus low-dose ipilimumab as a promising option in patients with microsatellite instability–high gastric cancer.
Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL
Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who achieved complete response at 2 years.
Preoperative Counseling Increases Shared Decision-Making in CRC Surgery
Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.
Promising Treatment To Raise the Standard of Care in Lower-Risk MDS-Related Anemia
CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.
microRNA-based Signatures Predict irAEs in Patients Receiving Anti-PD1 Treatment
Data from a study shared at the 2025 ASCO Annual Meeting showed that a microRNA-based model was able to predict irAEs in various cancers for…
FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases
The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.
Iopofosine I 131 Shows Preliminary Survival Benefit in Pediatric R/R Glioma
The safety profile of iopofosine I 131 in the phase 1b CLOVER-2 trial appears consistent with prior reports of the agent.